MKI67 and neoplasm: Traditional clinical markers (such as ER/PR, HER2, and Ki-67) primarily reflect tumor characteristics such as hormone receptor status and proliferation rate, but they may not fully capture the complexity of BC, especially in more aggressive subtypes like triple-negative breast cancer.